The trial's principal investigator Pasi Janne said the results support osimertinib "as standard of care" for EGFR-mutated cancer patients. Janne also noted that AstraZeneca's drug "did not impose any ...

The global lung cancer surgery market is projected to reach USD 1.48 billion in 2025, and is expected to expand further to ...

A meta-analysis of nearly 3.9 million participants shows people with allergies have significantly lower odds of developing ...